A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Study Details
Study Description
Brief Summary
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Phases 1 and 2: Tolinapant + Oral Decitabine/Cedazuridine Tolinapant, orally, once daily (QD) on Days 1 to 7 and 15 to 21 of each 28-day cycle in combination with oral decitabine/cedazuridine fixed-dose combination (FDC) tablet, QD on days determined by the Lead-in Phase during each 28-day cycle. The starting dose of tolinapant will be escalated stepwise in successive cohorts until the RP2D is determined. Based on RP2D and results determined from Phase 1 participants would receive tolinapant at the identified RP2D in combination with decitabine/cedazuridine, FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle in Phase 2. |
Drug: Tolinapant
Capsule for oral administration
Other Names:
Drug: Decitabine + Cedazuridine
Tablet for oral administration
Other Names:
|
| Experimental: Phase 1: Oral Decitabine/Cedazuridine Decitabine/cedazuridine FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle. |
Drug: Decitabine + Cedazuridine
Tablet for oral administration
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs) [Up to 54 months]
This will be evaluated by looking at the number of participants with treatment-related adverse events, serious adverse events (SAEs), and dose-limiting toxicities (DLTs), which are medical problems severe enough to stop study doctors from increasing a treatment dose.
- Phase 2: Antitumor Activity Assessed by Overall Response Rate (ORR) Based on 2014 Lugano Classification Using Computerized Tomography (CT) Imaging as the Primary Modality [Up to 54 months]
Secondary Outcome Measures
- Phase 1: Number of Participants With TEAEs, SAEs and DLTs in the Oral Decitabine/Cedazuridine Arm [Up to 54 months]
- Ph 1 & 2: AUC: Area Under the Plasma Concentration-Time Curve [Up to 50 months]
- Ph 1 & 2: Cmax: Maximum Observed Plasma Concentration [Up to 50 months]
- Ph 1 & 2: Cmin: Minimum Observed Plasma Concentration at Steady State [Up to 50 months]
- Ph 1 & 2: Tmax: Time to Maximum Observed Plasma Concentration [Up to 50 months]
- Ph 1 & 2: t½: Apparent Elimination Half-Life [Up to 50 months]
- Phase 2: Duration of response (DOR) Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Percentage of Participants With Complete Response (CR) Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Percentage of Participants With Partial Response (PR) Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Progression-Free Survival (PFS) Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Disease Control Rate (DCR) Assessed as Percentage of Participants With Disease Control Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Overall Survival (OS) Based on the Lugano Classification Using CT Imaging as the Primary Modality [Up to 54 months]
- Phase 2: Percentage of Participants With DOR, CR, PR, PFS, DCR,and OS Based on the Lugano Classification Using CT Along With PET Imaging Assessments [Up to 54 months]
Duration of response (DOR), complete response (CR), partial response (PR), progression-free survival (PFS), disease control rate (DCR)and overall survival (OS)
- Phase 2: Percentage of Participants With Anti-Tumor Activity Based on Assessment Using 2014 Lugano Classification With Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) [Up to 54 months]
Anti-tumor activity in terms of ORR, DOR, CR, PR, and PFS will be evaluated based on assessment using 2014 Lugano Classification with LYRIC.
- Phase 2: Percentage of Participants With Anti-Tumor Activity Based on PTCL Subtypes Anti-tumor activity in terms of ORR, DOR, DCR, CR, and PR will be evaluated based on PTCL subtypes (using both pathology and molecular markers). [Up to 54 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants with expected life expectancy of >12 weeks.
-
Participants must have histologically confirmed R/R PTCL (local pathology report) as defined by 2016 World Health Organization (WHO) classification. The following subtypes are eligible for the study:
-
Extranodal natural killer (NK)/T-cell lymphoma nasal type.
-
Enteropathy-associated T-cell lymphoma.
-
Monomorphic epitheliotropic intestinal T-cell lymphoma.
-
Hepatosplenic T-cell lymphoma.
-
Subcutaneous panniculitis-like T-cell lymphoma.
-
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
-
Angioimmunoblastic T-cell lymphoma.
-
Follicular peripheral T-cell lymphoma.
-
Nodal peripheral T-cell with T-follicular helper (THF) phenotype.
-
Anaplastic large-cell lymphoma (ALCL).
-
Participants must have evidence of progressive disease and must have received at least two prior systemic therapies.
-
Participants must have measurable disease by contrast-enhanced diagnostic CT (at least 1 nodal lesion >1.5 centimeters (cm) or extranodal lesions >1.0 cm).
-
Participants with CD30-positive disease must have received, be ineligible for, or intolerant to brentuximab vedotin.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
-
Acceptable organ function as per protocol.
-
Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Exclusion Criteria:
-
Prior treatment with tolinapant or any hypomethylating agent.
-
Hypersensitivity to tolinapant or oral decitabine/cedazuridine, excipients of the drug product, or other components of the study treatment regimen.
-
Poor medical risk because of systemic diseases (e.g., uncontrolled infections) in addition to the qualifying disease under study.
-
Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of tolinapant.
-
A history of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:
-
Abnormal left ventricular ejection fraction.
-
Congestive cardiac failure of Grade ≥3.
-
Unstable cardiac disease.
-
History or presence of complete left bundle branch block, third-degree heart block, cardiac pacemaker, or clinically significant arrhythmia.
-
History of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.
-
Screening 12-lead electrocardiogram (ECG) with measurable QTc interval of ≥470 milliseconds (msec) (according to either Fridericia's or Bazett's correction).
-
Any other condition that, in the opinion of the investigator, could put the participant at increased cardiac risk.
-
Known history of human immunodeficiency virus (HIV) infection; or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
-
Grade 3 or greater neuropathy.
-
Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol treatment or assessments.
-
Prior anticancer treatments or therapies within the indicated time window before first dose of study treatment (tolinapant), as follows:
-
Cytotoxic chemotherapy or radiotherapy within 4 weeks prior.
-
Monoclonal antibodies within 4 weeks prior.
-
At least 12 weeks must have elapsed since chimeric antigen receptor T-cell (CAR-T) infusion.
-
Small molecules or biologics (investigational or approved) within the longer of 3 weeks or 5 half-lives before study treatment.
-
Monoclonal antibody treatment for rheumatologic conditions within 4 weeks of study drug initiation.
-
Concurrent second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy or superficial bladder cancer.
-
Any concurrent second malignancy that is metastatic.
-
Known central nervous system (CNS) lymphoma.
-
Participants with a history of allogeneic transplant are excluded from this study.
-
Autotransplant within 100 days of the first dose of the study drug(s).
-
Systemic corticosteroids >10 mg prednisone equivalent within 7 days of the first dose of study drug(s).
-
Anti-T-cell directed therapy:
-
Lymphotoxic agents (e.g., anti-CD52) in the past 12 months.
-
Inhibitory drugs (e.g., calcineurin inhibitors) within 4 weeks of the first dose of study drug(s).
-
Use of a concomitant medication which is a moderate or strong CYP3A4 inhibitor/inducer within 2 weeks of the start of the study.
-
Use of any vaccine within 10 days of the first dose of the study drug(s).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rochester Skin Lymphoma Medical Group, PLLC | Fairport | New York | United States | 14450 |
Sponsors and Collaborators
- Astex Pharmaceuticals, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ASTX660-03
- 2021-005338-40